公开(公告)号：US12152266B2

公开(公告)日：2024-11-26

申请号：US18532631

申请日：2023-12-07

Applicant: Shuang Liu

Inventor： Shuang Liu ,  Haocheng Chen ,  Jinhao Liu ,  Jinhui Liu ,  Wei Li ,  Yinshi Sun

IPC: C12P21/06 ,  A61K9/19 ,  A61K35/28 ,  A61K35/32 ,  A61K35/34 ,  A61K35/36 ,  A61K35/38

Abstract: A novel method for preparing an active protein peptide from connective tissue which includes steps of: connective tissue acquisition, segmenting, washing, pulverization, pH adjustment, enzymolysis, filtration, ultrafiltration, nanofiltration concentration, sterilization, freeze-drying, etc. The connective tissue protein peptide obtained by the method of the invention has features of high peptide content, high activity, etc., and the prepared active protein peptide of the connective tissue is easily absorbed by the human body, and has functions of preventing and/or alleviating and/or treating related diseases. Further, the method includes operation steps that are simple and easy to perform, which has low energy consumption, appropriate and effective utilization of animal natural resources, as well as environmental friendly, non pollution of environment, and low production costs, which is suitable for large-scale industrial production, and the purpose of efficiently preparing an protein active peptide from connective tissue can be achieved.

公开(公告)号：US20180362504A1

公开(公告)日：2018-12-20

申请号：US16062423

申请日：2016-12-15

Applicant: Joseph FOX ,  Xinqiao JIA ,  Will TROUT ,  Joel ROSENTHAL ,  Han ZHANG ,  Yinzhi FANG ,  Colin THORPE ,  Shuang LIU ,  Yixin XIE

Inventor： Joseph FOX ,  Xinqiao JIA ,  Will TROUT ,  Joel ROSENTHAL ,  Han ZHANG ,  Yinzhi FANG ,  Colin THORPE ,  Shuang LIU ,  Yixin XIE

IPC: C07D401/14 ,  C07D401/04 ,  C12P17/16

Abstract: A method for catalytically converting a dihydrotetrazine 1 into a tetrazine 2, wherein one R group on the dihydrotetrazine 1 is a substituted or unsubstituted aryl, heteroaryl, alkyl, alkenyl, alkynyl, carbonyl, or heteroatom-containing group, and the other R group is selected from the group consisting of H and substituted or unsubstituted aryl, heteroaryl, alkyl, alkenyl, alkynyl, carbonyl,—or heteroatom-containing groups; 1, 2 wherein the method comprises oxidizing dihydrotetrazine 1 in a reaction medium in the presence of a catalyst and a stoichiometric oxidant.

公开(公告)号：US08575114B2

公开(公告)日：2013-11-05

申请号：US13052171

申请日：2011-03-21

Applicant: Shuang Liu ,  Cheng Guo

Inventor： Shuang Liu ,  Cheng Guo

IPC: A01N43/04 ,  A61K31/70 ,  C07H5/04 ,  C07H5/06

CPC classification number: A61K31/706

Abstract: The present invention relates to compounds which are inhibitors of sodium dependent glucose co-transporter-2 (SGLT-2). These compounds are used in the treatment of various disorders, including diabetes, impaired glucose tolerance, insulin resistance, retinopathy, nephropathy, neuropathy, cataracts, hyperglycemia, hyperinsulinemia, hyperchlolesterolemia, elevated blood level of free fatty acids or glycerol, hyperlipidemia, hypertriglyceridemia, obesity, wound healing, tissue ischemia, atherosclerosis, and hypertension. These compounds and compositions are also useful for treating and preventing kidney stones, hyperuricemia, gout, and hyponatremia. Methods of making these compounds are also described in the present invention.

Abstract translation: 本发明涉及作为钠依赖性葡萄糖共转运体-2（SGLT-2）抑制剂的化合物。 这些化合物用于治疗各种疾病，包括糖尿病，葡萄糖耐量降低，胰岛素抵抗，视网膜病变，肾病，神经病，白内障，高血糖症，高胰岛素血症，高胆固醇血症，游离脂肪酸或甘油血液水平升高，高脂血症，高甘油三酯血症，肥胖 伤口愈合，组织缺血，动脉粥样硬化和高血压。 这些化合物和组合物还可用于治疗和预防肾结石，高尿酸血症，痛风和低钠血症。 制备这些化合物的方法也在本发明中描述。

公开(公告)号：US07956050B2

公开(公告)日：2011-06-07

申请号：US11487884

申请日：2006-07-17

Applicant: Bruce F. Molino ,  Shuang Liu ,  Aruna Sambandam ,  Peter R. Guzzo ,  Min Hu ,  Congxiang Zha ,  Kassoum Nacro ,  David D. Manning ,  Matthew L. Isherwood ,  Kristen N. Fleming ,  Wenge Cui ,  Richard E. Olson

Inventor： Bruce F. Molino ,  Shuang Liu ,  Aruna Sambandam ,  Peter R. Guzzo ,  Min Hu ,  Congxiang Zha ,  Kassoum Nacro ,  David D. Manning ,  Matthew L. Isherwood ,  Kristen N. Fleming ,  Wenge Cui ,  Richard E. Olson

IPC: A61P25/00 ,  A61K31/55 ,  C07D223/16

CPC classification number: C07D223/16 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04

Abstract: The compounds of the present invention are represented by the following aryl- and heteroaryl-substituted tetrahydrobenzazepine and dihydrobenzazapine derivatives having formulae I(A-E) and formula (II): where the carbon atom designated * is in the R or S configuration, and the substituents X and R1-R9 are as defined herein.

Abstract translation: 本发明的化合物由以下芳基 - 和杂芳基取代的四氢苯并吖庚因和具有式I（AE）和式（II）的二氢苯并氮杂衍生物表示：其中指定为*的碳原子为R或S构型， X和R 1 -R 9如本文所定义。

公开(公告)号：US20100292242A1

公开(公告)日：2010-11-18

申请号：US12777728

申请日：2010-05-11

Applicant: Shuang Liu ,  Bruce F. Molino ,  Kassoum Nacro

Inventor： Shuang Liu ,  Bruce F. Molino ,  Kassoum Nacro

IPC: A61K31/472 ,  C07D401/10 ,  A61K31/501 ,  A61K31/497 ,  C07D217/14 ,  A61K31/4725 ,  C07D471/04 ,  A61P25/00 ,  A61P25/24 ,  A61P15/00

CPC classification number: C07D401/04 ,  C07D217/02 ,  C07D217/12 ,  C07D217/14 ,  C07D413/04 ,  C07D471/04

Abstract: Novel aryl, heteroaryl, and non-aromatic heterocyle substituted tetrahydroisoquinolines are described in the present invention. These compounds are used in the treatment of various neurological and physiological disorders. Methods of making these compounds are also described in the present invention.

Abstract translation: 本发明描述了新的芳基，杂芳基和非芳族杂环取代的四氢异喹啉。 这些化合物用于治疗各种神经和生理疾病。 制备这些化合物的方法也在本发明中描述。

公开(公告)号：US20100137287A1

公开(公告)日：2010-06-03

申请号：US12598882

申请日：2008-05-08

Applicant: Peter R. Guzzo ,  Bruce F. Molino ,  Wenge Cui ,  Shuang Liu ,  Richard E. Olson

Inventor： Peter R. Guzzo ,  Bruce F. Molino ,  Wenge Cui ,  Shuang Liu ,  Richard E. Olson

IPC: A61K31/5513 ,  C07D243/14 ,  A61P25/00

CPC classification number: C07D243/14 ,  C07D401/04 ,  C07D403/04 ,  C07D403/12 ,  C07D405/14 ,  C07D471/04

Abstract: The aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepine derivative compounds of the present invention are represented by formulae 1(A-D) having the following structure: where the substituents X and R1-R8 are as defined herein.

Abstract translation: 本发明的芳基 - 和杂芳基取代的四氢苯并-1,4-二氮杂衍生物化合物由具有以下结构的式1（A-D）表示：其中取代基X和R 1 -R 8如本文所定义。

公开(公告)号：US07629363B2

公开(公告)日：2009-12-08

申请号：US11226556

申请日：2005-09-14

Applicant: Balekudru Devadas ,  John Walker ,  Shaun R. Selness ,  Terri L. Boehm ,  Richard C. Durley ,  Rajesh Devraj ,  Brian S. Hickory ,  Paul V. Rucker ,  Kevin D. Jerome ,  Heather M. Madsen ,  Edgardo Alvira ,  Michele A. Promo ,  Radhika M. Blevis-Bal ,  Laura D. Marruto ,  Jeff Hitchcock ,  Thomas Owen ,  Win Naing ,  Li Xing ,  Huey S. Shieh ,  Aruna Sambandam ,  Shuang Liu ,  Ian L. Scott ,  Kevin F. McGee

Inventor： Balekudru Devadas ,  John Walker ,  Shaun R. Selness ,  Terri L. Boehm ,  Richard C. Durley ,  Rajesh Devraj ,  Brian S. Hickory ,  Paul V. Rucker ,  Kevin D. Jerome ,  Heather M. Madsen ,  Edgardo Alvira ,  Michele A. Promo ,  Radhika M. Blevis-Bal ,  Laura D. Marruto ,  Jeff Hitchcock ,  Thomas Owen ,  Win Naing ,  Li Xing ,  Huey S. Shieh ,  Aruna Sambandam ,  Shuang Liu ,  Ian L. Scott ,  Kevin F. McGee

IPC: A61K31/44 ,  C07D211/02

CPC classification number: C07D213/64 ,  C07D213/69 ,  C07D213/70 ,  C07D213/74 ,  C07D213/75 ,  C07D213/79 ,  C07D213/84 ,  C07D213/85 ,  C07D215/22 ,  C07D401/04 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/04 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/06 ,  C07D409/14 ,  C07D413/10

Abstract: Disclosed are compounds Formula I and pharmaceutically acceptable salts thereof, wherein R1, R2, R3/R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.

Abstract translation: 公开了式I化合物及其药学上可接受的盐，其中R 1，R 2，R 3 / R 4和R 5在本文中定义。 这些化合物可用于治疗由不受调节的p38 MAP激酶和/或TNF活性引起或加重的疾病和病症。 还公开了含有化合物的药物组合物，制备化合物的方法和使用该化合物的治疗方法。

公开(公告)号：US20090253906A1

公开(公告)日：2009-10-08

申请号：US12417598

申请日：2009-04-02

Applicant: Bruce F. MOLINO ,  Shuang LIU ,  Peter R. GUZZO ,  James P. BECK

Inventor： Bruce F. MOLINO ,  Shuang LIU ,  Peter R. GUZZO ,  James P. BECK

IPC: C07D413/14 ,  C07D401/14 ,  C07D401/04 ,  C07D403/14 ,  C07D409/14 ,  C07D409/04 ,  C07D413/04 ,  C07D417/14 ,  C07D417/04

CPC classification number: C07D417/04 ,  A61K31/4709 ,  A61K31/4741 ,  A61K31/4743 ,  A61K31/502 ,  A61K31/517 ,  A61K31/53 ,  C07D217/00 ,  C07D217/04 ,  C07D217/08 ,  C07D217/12 ,  C07D217/14 ,  C07D217/16 ,  C07D217/20 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D407/04 ,  C07D409/04 ,  C07D409/12 ,  C07D409/14 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04

Abstract: The compounds of the present invention are represented by the chemical structure found in Formula (I): wherein: the carbon atom designated * is in the R or S configuration; and X is a fused bicyclic carbocycle or heterocycle selected from the group consisting of benzofuranyl, benzo[b]thiophenyl, benzoisothiazolyl, benzoisoxazolyl, indazolyl, indolyl, isoindolyl, indolizinyl, benzoimidazolyl, benzooxazolyl, benzothiazolyl, benzotriazolyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3 -a]pyridinyl, thieno[2,3-b]pyridinyl, thieno[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, indenyl, indanyl, dihydrobenzocycloheptenyl, tetrahydrobenzocycloheptenyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, indolinyl, naphthyl, tetrahydronaphthyl, quinolinyl, isoquinolinyl, 4H-quinolizinyl, 9aH-quinolizinyl, quinazolinyl, cinnolinyl, phthalazinyl, quinoxalinyl, benzo[1,2,3]triazinyl, benzo[1,2,4]triazinyl, 2H-chromenyl, 4H-chromenyl, and a fused bicyclic carbocycle or fused bicyclic heterocycle optionally substituted with substituents (1 to 4 in number) as defined in R14; with R1, R2, R3, R4, R5, R6, R7, R8, and R14 defined herein.

Abstract translation: 本发明的化合物由式（I）中所示的化学结构表示：其中：指定为*的碳原子为R或S构型; 并且X是选自苯并呋喃基，苯并[b]噻吩基，苯并异噻唑基，苯并异恶唑基，吲唑基，吲哚基，异吲哚基，吲嗪基，苯并咪唑基，苯并恶唑基，苯并噻唑基，苯并三唑基，咪唑并[1,2-a ]吡啶基，吡唑并[1,5-a]吡啶基，[1,2,4]三唑并[4,3-a]吡啶基，噻吩并[2,3-b]吡啶基，噻吩并[3,2-b] 二氢苯并噻吩基，二氢苯并呋喃基，二氢苯并噻吩基，四氢萘基，喹啉基，异喹啉基，4H-喹啉基，9H-喹啉基，喹唑啉基，噌啉基，酞嗪基，喹喔啉基， 苯并[1,2,3]三嗪基，苯并[1,2,4]三嗪基，2H-色烯基，4H-色烯基和稠合的双环碳环或稠合双环杂环，其任选被如所定义的取代基（数目为1至4） 在R14; 本文定义的R1，R2，R3，R4，R5，R6，R7，R8和R14。

公开(公告)号：US20080124273A1

公开(公告)日：2008-05-29

申请号：US11811064

申请日：2007-06-08

Applicant: Shuang Liu ,  Zhengjie He

Inventor： Shuang Liu ,  Zhengjie He

IPC: A61K51/04 ,  C07F13/00

CPC classification number: C07F13/005

Abstract: This invention relates to novel cationic crown-ether containing metal complexes, methods of preparing the cationic crown-ether containing metal complexes, and radiopharmaceutical compositions comprising the cationic crown-ether containing metal complexes. This invention relates particularly to cationic crown-ether containing 99mTc complex radiopharmaceuticals for diagnosis of cardiovascular disorders and cancer. This invention further relates to cationic crown-ether containing 186/188Re complex radiopharmaceuticals for radiotherapy of cardiovascular disorders and cancer.

Abstract translation: 本发明涉及新型含阳离子冠醚的金属络合物，制备含阳离子冠醚的金属络合物的方法，以及包含阳离子冠醚的金属络合物的放射性药物组合物。 本发明特别涉及用于诊断心血管疾病和癌症的含有99m Tc复合物放射性药物的阳离子冠醚。 本发明还涉及含有用于放射治疗心血管疾病和癌症的阳离子冠醚，其包含用于放射治疗心血管疾病和癌症的146复方放射性药物。

公开(公告)号：US07319149B2

公开(公告)日：2008-01-15

申请号：US10864792

申请日：2004-06-09

Applicant: Shuang Liu

Inventor： Shuang Liu

IPC: C07D401/02

CPC classification number: C07F13/005 ,  A61K51/0478 ,  A61K51/0482 ,  C07D213/81 ,  C07D213/82 ,  C07F9/58

Abstract: Chelants and macrocyclic metal complexes thereof, methods of preparing the chelants and macrocyclic metal complexes, and radiopharmaceutical compositions comprising the macrocyclic metal complexes are disclosed. Methods of using the macrocyclic metal complexes as radiopharmaceuticals for the diagnosis of cardiovascular disorders, infectious diseases and cancer are also disclosed. Chelants as bifunctional chelators (BFCs) for the radiolabeling of target-specific biomolecules, such as proteins, peptides, peptidomimetics, non-peptide receptor ligands, enzyme inhibitors, and enzyme substrates are disclosed. Methods of using macrocyclic metal complexes containing the chelant-biomolecule conjugates as target-specific diagnostic radiopharmaceuticals that selectively localize at sites of disease and allow an image to be obtained of the loci using gamma scintigraphy are disclosed. Methods of use of the radiopharmaceuticals as imaging agents for the diagnosis of cardiovascular disorders, such as thromboembolic disease or atherosclerosis, infectious disease and cancer are further disclosed.

Abstract translation: 公开了螯合剂及其大环金属络合物，制备螯合剂和大环金属配合物的方法，以及包含大环金属络合物的放射性药物组合物。 还公开了将大环金属络合物用作放射性药物用于诊断心血管疾病，感染性疾病和癌症的方法。 公开了用于靶标特异性生物分子例如蛋白质，肽，肽模拟物，非肽受体配体，酶抑制剂和酶底物的放射性标记的双功能螯合剂（BFC）的螯合剂。 公开了使用含有螯合剂 - 生物分子共轭物的大环金属络合物作为靶向特异性诊断放射性药物的方法，其在疾病部位选择性定位并允许使用γ闪烁扫描获得基因座的图像。 进一步公开了使用放射性药物作为诊断心血管疾病如血栓栓塞性疾病或动脉粥样硬化，感染性疾病和癌症的显像剂的方法。